The protective effect of Thiamine (vitamin B1) for Bortezomib induced peripheral neuropathy in multiple myeloma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190116042379N1

Enrollment

Registered

2019-02-14

Start date

2019-01-16

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathy.

Interventions

Intervention 1: Intervention group: Patients treated with bortezomibe with a dose of 1.3 mg per m2 and vitamin B1 simultaneously. (Vitamin B1 at a dose of 300 mg per day orally). Intervention 2: Contr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: who were suspected to receive Bortezomib based chemotherapy regimen

Exclusion criteria

Exclusion criteria: do not have interfering factors such as: Previous history of symptomatic peripheral neuropathy, Diabetes mellitus, End stage renal disease, history of alcohol abuse, and any other neuromuscular disease

Design outcomes

Primary

Measure	Time frame
Neuropathy. Timepoint: 4month. Method of measurement: experimental symptom-based questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhazal Rafiaei

Esfahan University of Medical Sciences

ghazalrafiaei@gmail.com+98 31 3261 3680

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026